New strategies for the treatment of hyperparathyroidism incorporating calcimimetics

Bibliography

• Silverberg SJ, Bilezikian JP. The diagnosis and management of asymptomatic primary hyperparathyroidism. Nat Clin Pract Endocrinol Metab 2006;2(9):494-503
   PubMedGoogle Scholar
• Goodman WG. Recent developments in the management of secondary hyperparathyroidism. Kidney Int 2001;59(3):1187-201
   PubMed Web of Science ®Google Scholar
• Leboff MS, Shoback D, Brown EM, et al. Regulation of parathyroid hormone release and cytosolic calcium by extracellular calcium in dispersed and cultured bovine and pathological human parathyroid cells. J Clin Invest 1985;75(1):49-57
   PubMed Web of Science ®Google Scholar
• Brown EM. Calcium receptor and regulation of parathyroid hormone secretion. Rev Endocr Metab Disord 2000;1(4):307-15
   PubMedGoogle Scholar
• Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993;366(6455):575-80
   PubMed Web of Science ®Google Scholar
• Nemeth EF, Steffey ME, Hammerland LG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998;95(7):4040-5
   PubMed Web of Science ®Google Scholar
• Nemeth EF, Heaton WH, Miller M, et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 2004;308(2):627-35
   PubMed Web of Science ®Google Scholar
• Block GA, Martin KJ, De Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350(15):1516-25
   PubMed Web of Science ®Google Scholar
• Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005;16(3):800-7
   PubMed Web of Science ®Google Scholar
• Peacock M, Bilezikian JP, Klassen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005;90(1):135-41
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol 2005;288(2):F253-64
   PubMed Web of Science ®Google Scholar
• Naveh-Many T, Rahamimov R, Livni N, Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 1995;96(4):1786-93
   PubMed Web of Science ®Google Scholar
• Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 1997;29(4):496-502
   PubMed Web of Science ®Google Scholar
• Martinez I, Saracho R, Montenegro J, Llach F. A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 1996;11(Suppl 3):22-8
   PubMedGoogle Scholar
• Bricker NS. On the pathogenesis of the uremic state. An exposition of the “trade-off hypothesis”. N Engl J Med 1972;286(20):1093-9
   PubMed Web of Science ®Google Scholar
• Drueke TB. Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 2000;11(6):1141-52
   PubMed Web of Science ®Google Scholar
• Fukuda N, Tanaka H, Tominaga Y, et al. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993;92(3):1436-43
   PubMed Web of Science ®Google Scholar
• Kifor O, Moore FD Jr, Wang P, et al. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996;81(4):1598-606
   PubMed Web of Science ®Google Scholar
• Gogusev J, Duchambon P, Hory B, et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997;51(1):328-36
   PubMed Web of Science ®Google Scholar
• Kilav R, Silver J, Naveh-Many T. Parathyroid hormone gene expression in hypophosphatemic rats. J Clin Invest 1995;96(1):327-33
   PubMed Web of Science ®Google Scholar
• Almaden Y, Hernandez A, Torregrosa V, et al. High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Am Soc Nephrol 1998;9(10):1845-52
   PubMed Web of Science ®Google Scholar
• Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342(20):1478-83
   PubMed Web of Science ®Google Scholar
• Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res 2002;17(12):2094-105
   PubMed Web of Science ®Google Scholar
• Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15(8):2208-18
   PubMed Web of Science ®Google Scholar
• Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS Waves 1, 3, and 4 Study. J Am Soc Nephrol 2005;16(6):1788-93
   PubMed Web of Science ®Google Scholar
• Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67(3):1179-87
   PubMed Web of Science ®Google Scholar
• Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44(5 Suppl 2):34-8
   PubMed Web of Science ®Google Scholar
• K/DOQI Guidelines 2003. Am J Kidney Dis 2003;42(4 Suppl 3):S1-201
   Google Scholar
• Fernandez-Martin JL, Gorriz JL, Ketteler M, et al. Guidelines and bone mineral management in facilities in the pan-European COSMOS study [Abstract MP359]. Nephrol Dial Transplant 2006;21(Suppl 4):iv420
   Google Scholar
• Perez Garcia R, Garcia F, Martin-Malo A, et al. Progression of bone mineral metabolism parameters in the first year after hemodialysis (HD) initiation in Spain: ANSWER Study [Abstract TH-PO138]. J Am Soc Nephrol 2006;17:135A
   Google Scholar
• Block GA, Klassen P, Danese M. Association between proposed NKF-K/DOQI bone metabolism and disease guidelines and mortality risk in hemodialysis patients [Abstract SA-PO801]. J Am Soc Nephrol 2003;14:474A
   Google Scholar
• Sensipar® (cinacalcet HCl). Full Prescribing Information, Amgen, Inc., Thousand Oaks, CA; 2007
   Google Scholar
• Bajpai M, Esmay J, Chi V, et al. In vitro metabolism and prediction of drug-drug interactions of the calcimimetic agent cinacalcet HCl [Abstract 212]. Drug Metab Rev 2005;37(Suppl 2):124
   Google Scholar
• Padhi D, Salfi M, Erbeck N, et al. Cinacalcet HCl does not affect CYP3A activity, a metabolic pathway for commonly used immunosuppressive agents [Abstract T-PO-1602]. World Congress of Nephrology. 2007 April 21 – 25; Rio de Janeiro, Brazil
   Google Scholar
• Harris RZ, Salfi M, Posvar E, et al. Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol 2007;63(2):159-63
   PubMedGoogle Scholar
• Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369(1):23-37
   PubMed Web of Science ®Google Scholar
• Drug interaction table (cytochrome P450 system) 2007. Available from: medicine.iupui.edu/flockhart/table.htm [Accessed 26 February 2008]
   Google Scholar
• Padhi D, Sullivan JT. Cinacalcet does not affect the pharmacokinetics or pharmacodynamics of warfarin. Drugs R&D 2007;8(2):79-87
   PubMedGoogle Scholar
• Harris RZ, Sullivan JT, Salfi M, Padhi D. Pharmacokinetics of cinacalcet HCl when administered with ketoconazole. Clin Pharmacokinet 2007;46(6):495-501
   PubMed Web of Science ®Google Scholar
• Harris RZ, Padhi D, Marbury TC, et al. Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am J Kidney Dis 2004;44(6):1070-6
   PubMed Web of Science ®Google Scholar
• Padhi D, Harris RZ, Salfi M, Sullivan JT. No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar/Mimpara). Clin Pharmacokinet 2005;44(5):509-16
   PubMed Web of Science ®Google Scholar
• Kawata T, Imanishi Y, Kobayashi K, et al. Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels. J Bone Miner Metab 2006;24(4):300-6
   PubMed Web of Science ®Google Scholar
• Levi R, Ben-Dov IZ, Lavi-Moshayoff V, et al. Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor AUF1. J Am Soc Nephrol 2006;17(1):107-12
   PubMed Web of Science ®Google Scholar
• Sela-Brown A, Silver J, Brewer G, Naveh-Many T. Identification of AUF1 as a parathyroid hormone mRNA 3′-untranslated region-binding protein that determines parathyroid hormone mRNA stability. J Biol Chem 2000;275(10):7424-9
   PubMed Web of Science ®Google Scholar
• Colloton M, Shatzen E, Miller G, et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 2005;67(2):467-76
   PubMed Web of Science ®Google Scholar
• Mizobuchi M, Hatamura I, Ogata H, et al. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol 2004;15(10):2579-87
   PubMed Web of Science ®Google Scholar
• Rodriguez ME, Almaden Y, Canadillas S, et al. The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands. Am J Physiol 2007;295(5):F1390-1395
   Google Scholar
• Henley C, Colloton M, Cattley RC, et al. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar®/Mimpara®) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 2005;20:1370-7
   PubMed Web of Science ®Google Scholar
• Lopez I, Aguilera-Tejero E, Mendoza FJ, et al. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 2006;17(3):795-804
   PubMed Web of Science ®Google Scholar
• Wada M, Ishii H, Furuya Y, et al. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 1998;53(2):448-53
   PubMed Web of Science ®Google Scholar
• Ishii H, Wada M, Furuya Y, et al. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone 2000;26(2):175-82
   PubMed Web of Science ®Google Scholar
• Shalhoub V, Henley C, Shatzen E, et al. Calcimimetic administration prevents renal osteodystrophy in rats with adenine-induced secondary hyperparathyroidism (HPT) [Abstract S-PO-0304]. World Congress of Nephrology. 2007 April 21 – 25; Rio de Janeiro, Brazil
   Google Scholar
• Kawata T, Kobayashi N, Furuya Y, et al. The calcimimetic compound cinacalcet HCl ameliorates mineral and bone disorder in 5/6 nephrectomized rats [Abstract TH-PO128]. J Am Soc Nephrol 2006;17:133A
   Google Scholar
• Jean G, Chazot C, Charra B. 12 months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism: effect on bone markers. Clin Nephrol 2007;68(1):63-4
   PubMedGoogle Scholar
• Reynolds JL, Joannides AJ, Skepper JN, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004;15(11):2857-67
   PubMed Web of Science ®Google Scholar
• Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000;87(7):E10-17
   PubMed Web of Science ®Google Scholar
• Jono S, Nishizawa Y, Shioi A, Morii H. 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 1998;98(13):1302-6
   PubMed Web of Science ®Google Scholar
• Shalhoub V, Shatzen E, Henley C, et al. Calcification inhibitors and Wnt signaling proteins are implicated in bovine artery smooth muscle cell calcification in the presence of phosphate and vitamin D sterols. Calcif Tissue Int 2006;79(6):431-42
   PubMed Web of Science ®Google Scholar
• Andress DL. Vitamin D treatment in chronic kidney disease. Semin Dial 2005;18(4):315-21
   PubMed Web of Science ®Google Scholar
• Brickman AS, Coburn JW, Norman AW. Action of 1,25-dihydroxycholecalciferol, a potent, kidney-produced metabolite of vitamin D, in uremic man. N Engl J Med 1972;287(18):891-5
   PubMed Web of Science ®Google Scholar
• Berl T, Berns AS, Hufer WE, et al. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study. Ann Intern Med 1978;88(6):774-80
   PubMedGoogle Scholar
• Li YC, Amling M, Pirro AE, et al. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 1998;139(10):4391-6
   PubMed Web of Science ®Google Scholar
• Demay MB, Kiernan MS, Deluca HF, Kronenberg HM. Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 1992;89(17):8097-101
   PubMed Web of Science ®Google Scholar
• Indridason OS, Quarles LD. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int 2000;57(1):282-92
   PubMed Web of Science ®Google Scholar
• Maung HM, Elangovan L, Frazao JM, et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001;37(3):532-43
   PubMed Web of Science ®Google Scholar
• Coburn JW, Salusky IB, Norris KC, Goodman WG. Oral and parenteral calcitriol for the management of end-stage renal disease. Contrib Nephrol 1991;90:166-82
   PubMedGoogle Scholar
• Korkor AB. Reduced binding of [3H]1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure. N Engl J Med 1987;316(25):1573-7
   PubMed Web of Science ®Google Scholar
• Imanishi Y, Inaba M, Nakatsuka K, et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004;65(5):1943-6
   PubMedGoogle Scholar
• Stubbs J, Liu S, Quarles LD. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 2007;20(4):302-8
   PubMed Web of Science ®Google Scholar
• Brown AJ, Dusso AS, Slatopolsky E. Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant 2002;17(Suppl 10):10-9
   PubMed Web of Science ®Google Scholar
• Ghazali A, Fardellone P, Pruna A, et al. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney Int 1999;55(6):2169-77
   PubMed Web of Science ®Google Scholar
• Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005;16(4):1115-25
   PubMed Web of Science ®Google Scholar
• Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006;70(10):1858-65
   PubMed Web of Science ®Google Scholar
• Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349(5):446-56
   PubMed Web of Science ®Google Scholar
• Malluche HH. Aluminium and bone disease in chronic renal failure. Nephrol Dial Transplant 2002;17(Suppl 2):21-4
   PubMedGoogle Scholar
• Alfrey AC, Hegg A, Craswell P. Metabolism and toxicity of aluminum in renal failure. Am J Clin Nutr 1980;33(7):1509-16
   PubMed Web of Science ®Google Scholar
• Mak RH, Turner C, Thompson T, et al. Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide. Br Med J (Clin Res Ed) 1985;291(6496):623-7
   PubMedGoogle Scholar
• Emmett M, Sirmon MD, Kirkpatrick WG, et al. Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis 1991;17(5):544-50
   PubMed Web of Science ®Google Scholar
• Qunibi WY, Hootkins RE, McDowell LL, et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004;65(5):1914-26
   PubMed Web of Science ®Google Scholar
• Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68(4):1815-24
   PubMed Web of Science ®Google Scholar
• Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15(7):1014-21
   PubMed Web of Science ®Google Scholar
• Meric F, Yap P, Bia MJ. Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy. Am J Kidney Dis 1990;16(5):459-64
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62(1):245-52
   PubMed Web of Science ®Google Scholar
• Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71(5):438-41
   PubMed Web of Science ®Google Scholar
• Braunlin W, Zhorov E, Guo A, et al. Bile acid binding to sevelamer HCl. Kidney Int 2002;62(2):611-9
   PubMed Web of Science ®Google Scholar
• Hergesell O, Ritz E. Phosphate binders in uraemia: pharmacodynamics, pharmacoeconomics, pharmacoethics. Nephrol Dial Transplant 2002;17(1):14-7
   PubMedGoogle Scholar
• Does sevelamer hydrochloride (Renagel) influence 25(OH)D3 and 1,25(OH)2D3 level in haemodialysis patients? 2005. Available from: www.ifcc.org/ejifcc/vol16no4/160412200501.htm
   Google Scholar
• Brezina B, Qunibi WY, Nolan CR. Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int Suppl 2004;(90):S39-45
   Google Scholar
• Duggal A, Hanus M, Zhorov E, et al. Novel dosage forms and regimens for sevelamer-based phosphate binders. J Ren Nutr 2006;16(3):248-52
   PubMedGoogle Scholar
• Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003;42(1):96-107
   PubMed Web of Science ®Google Scholar
• D'Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003;63(Suppl 85):S73-8
   Google Scholar
• Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 2005;68(6):2809-13
   PubMed Web of Science ®Google Scholar
• Altmann P, Barnett ME, Finn WF. Cognitive function in stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int 2007;71(3):252-9
   PubMed Web of Science ®Google Scholar
• Horl WH. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant 2004;19(Suppl 5):V2-8
   PubMed Web of Science ®Google Scholar
• De Francisco AL. Medical therapy of secondary hyperparathyroidism in chronic kidney disease: old and new drugs. Expert Opin Pharmacother 2006;7(16):2215-24
   PubMedGoogle Scholar
• Cunningham J. Achieving therapeutic targets in the treatment of secondary hyperparathyroidism. Nephrol Dial Transplant 2004;19(Suppl 5):V9-14
   Google Scholar
• Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003;63(1):248-54
   PubMed Web of Science ®Google Scholar
• Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003;14(3):575-83
   PubMed Web of Science ®Google Scholar
• Goodman WG, Hladik GA, Turner SA, et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002;13(4):1017-24
   PubMed Web of Science ®Google Scholar
• Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005;67(2):760-71
   PubMed Web of Science ®Google Scholar
• Sterrett JR, Strom J, Sturmvoll H-K, et al. Cinacalcet HCl (Sensipar®/Mimpara®) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 2007;68(1):10-7
   PubMed Web of Science ®Google Scholar
• Moe SM, Cunningham J, Bommer J, et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 2005;20(10):2186-93
   PubMed Web of Science ®Google Scholar
• Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005;68(4):1793-800
   PubMed Web of Science ®Google Scholar
• Chertow GM, Blumenthal S, Turner S, et al. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium and phosphorus. Clin J Am Soc Nephrol 2006;1:305-12
   PubMedGoogle Scholar
• Zeig S, Block G, Sugihara J, et al. Cinacalcet HCl administered alone or in combination with low-dose vitamin D sterol enables simultaneous achievement of PTH and calcium-phosphorus product (Ca × P) K/DOQI™ targets [Abstract F-PO757]. J Am Soc Nephrol 2005;16:501A
   Google Scholar
• Messa P, Villa G, Braun J, et al. The OPTIMA Study: lower doses of cinacalcet (Mimpara®/Sensipar®) are required to achieve KDOQI™ secondary hyperparathyroidism (HPT) targets in dialysis patients with less severe disease [Abstract MP324]. Nephrol Dial Transplant 2006;21(Suppl 4):iv407
   Google Scholar
• Charytan C, Coburn JW, Chonchol M, et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 2005;46(1):58-67
   PubMed Web of Science ®Google Scholar
• Schaefer RM, Bover J, Kleophas W, et al. The SENSOR Study: a study to evaluate the efficacy of administering cinacalcet (Mimpara®/Sensipar®) with the first meal after dialysis. Nephrol Dial Transplant 2006;21(4):iv288
   Google Scholar
• Messa P, Sindici C, Cannella G, et al. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 1998;54(5):1704-13
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Claes K, Kuypers D, et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant 2004;19(5):1281-7
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Naesens M, Claes K, et al. Tertiary ‘hyperphosphatoninism’ accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 2007;7(5):1193-200
   PubMed Web of Science ®Google Scholar
• Gwinner W, Suppa S, Mengel M, et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 2005;5(8):1934-41
   PubMed Web of Science ®Google Scholar
• Heaf J, Tvedegaard E, Kanstrup IL, Fogh-Andersen N. Hyperparathyroidism and long-term bone loss after renal transplantation. Clin Transplant 2003;17(3):268-74
   PubMed Web of Science ®Google Scholar
• Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med 1995;333(3):166-74
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Claes K, Kuypers D, et al. Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. Nephrol Dial Transplant 2005;20(8):1714-20
   PubMed Web of Science ®Google Scholar
• Serra AL, Schwarz AA, Wick FH, et al. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005;20(7):1315-9
   PubMed Web of Science ®Google Scholar
• Szwarc I, Argiles A, Garrigue V, et al. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Transplantation 2006;82(5):675-80
   PubMed Web of Science ®Google Scholar
• Apostolou T, Damianou L, Kotsiev V, et al. Treatment of severe hypercalcemia due to refractory hyperparathyroidism in renal transplant patients with the calcimimetic agent cinacalcet. Clin Nephrol 2006;65(5):374-7
   PubMedGoogle Scholar
• Apostolou T, Kollia K, Damianou L, et al. Hypercalcemia due to resistant hyperparathyroidism in renal transplant patients treated with the calcimimetic agent cinacalcet. Transplant Proc 2006;38(10):3514-6
   PubMedGoogle Scholar
• Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005;20(7):1311-4
   PubMed Web of Science ®Google Scholar
• Leca N, Lafttavi M, Gundroo A, et al. Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet. Am J Transplant 2006;6(10):2391-5
   PubMedGoogle Scholar
• El-Amm JM, Doshi MD, Singh A, et al. Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. Transplantation 2007;83(5):546-9
   PubMed Web of Science ®Google Scholar
• Serra AL, Savoca R, Huber AR, et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant 2007;22(2):577-83
   PubMed Web of Science ®Google Scholar
• Srinivas TR, Schold JD, Womer KL, et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol 2006;1:323-7
   PubMed Web of Science ®Google Scholar
• Helwig JJ, Musso MJ, Judes C, Nickols GA. Parathyroid hormone and calcium: interactions in the control of renin secretion in the isolated, nonfiltering rat kidney. Endocrinology 1991;129(3):1233-42
   PubMedGoogle Scholar
• Takami H, Ikeda Y, Okinaga H, Kameyama K. Recent advances in the management of primary hyperparathyroidism. Endocr J 2003;50(4):369-77
   PubMedGoogle Scholar
• Bilezikian JP, Potts JT Jr, Fuleihan GE, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002;87(12):5353-61
   PubMedGoogle Scholar
• Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88(12):5644-9
   PubMed Web of Science ®Google Scholar
• Rodgers SE, Perrier ND. Parathyroid carcinoma. Curr Opin Oncol 2006;18(1):16-22
   PubMed Web of Science ®Google Scholar
• Chertow GM, Block G, Correa-Rotter R, et al. Evaluation of cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial [Abstract PUB359]. J Am Soc Nephrol 2006;17:892A
   Google Scholar
• Narayan R, Perkins RM, Berbano EP, et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. Am J Kidney Dis 2007;49(6):801-13
   PubMed Web of Science ®Google Scholar
• Garside R, Pitt M, Anderson R, et al. The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective. Nephrol Dial Transplant 2007;22(5):1428-36
   PubMed Web of Science ®Google Scholar
• Ray JA, Valentine WJ, Palmer AJ. Cost utility analysis of cinacalcet in addition to standard of care in the UK. Nephrol Dial Transplant 2007;22(11):3355-7
   PubMedGoogle Scholar